WASHINGTON—The Federal Trade Commission on Tuesday challenged Illumina Inc.’s. proposed acquisition of Pacific Biosciences of California, a $1.2 billion deal in the life-sciences industry.
The FTC is bringing an administrative lawsuit alleging the biotech acquisition would allow Illumina to unlawfully maintain a monopoly in next-generation DNA sequencing by eliminating PacBio as a nascent competitor.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States United States Latest News, United States United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Digital banking app MoneyLion is launching stock-trading in 2020 - Business InsiderMoneyLion, an online lending startup that raised over $200 million touting itself as an affordable banking option, is adding stock-trading in 2020
Source: BusinessInsider - 🏆 729. / 51 Read more »
DuPont chairman says deal with IFF gives new company 'double the R&D' of competitorsInternational Flavors & Fragrances is merging with DuPont's nutrition and biosciences unit, creating a $45.4 billion consumer goods giant. when do these CEO's lose their jobs for stocks which under perform greatly? $IFF stock been awful in a huge stock market year. Accountability is needed.
Source: CNBC - 🏆 12. / 72 Read more »